PJSC Farmak pharmaceutical company (Kyiv) in April-July exported to the EU propofol, a medication that is used for artificial lung ventilation of patients with coronavirus (COVID-19), worth more than $635,000,
The company told Interfax-Ukraine that due to the shortage of this medication in the EU and its active use for treatment of COVID-19 patients the supplies of the medication were carried out without its registration at the EU’s profile agency, which is a mandatory condition for sale of drugs in Europe.
“Such an exclusion is connected with the crisis, and at the same time it shows the level of confidence in Ukrainian manufacturers and quality of their products,” the company said.
